Myst Therapeutics (Myst), a preclinical stage biotechnology company focused on developing selected TIL-based autologous T cell (PuriT™) therapy products for cancer, announced the appointment of George ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results